A second drug has shown the ability to slow the progression of the leading form of dementia.
Results of a study, released in a preliminary form by drug maker Eli Lilly, show their drug donanemab reduced the rate of cognitive decline of Alzheimer’s patients in a trial by between 27 and 35%.
Those on the drug were also better able
Read more…
Please follow and like us:
